Properties
What is it?
International Nonproprietary Name - Progesteronum Pharmacological group: Sex hormones and their antagonists Active substance: Progesterone 100 mg Progesterone 200 mg Excipients: Lactose monohydrate, Pregelatinized corn starch, Croscarmellose sodium, Hypromellose, Citric acid monohydrate, Magnesium stearate, Colloidal anhydrous silica. Dosage and administration: Progesterone dosage is determined individually, depending on the indication and efficacy. For menstrual cycle disorders, dysmenorrhea, premenstrual syndrome, luteal phase deficiency in the perimenopausal period, 100 mg of progesterone is prescribed daily, in the second phase of the menstrual cycle (natural or induced) for 10-20 days. For menstrual cycle disorders, dysmenorrhea, and premenstrual syndrome, treatment lasts for 3-6 consecutive cycles. In the perimenopausal period with luteal phase deficiency, progesterone treatment continues until menopause. In hormone replacement therapy, it is used in combination with estrogens, 100 mg of intravaginal progesterone daily, as sequential therapy from day 15 to day 25 of the cycle or daily as continuous therapy. In secondary amenorrhea, during progesterone testing, progesterone is prescribed intravaginally at 100 mg daily for 5-7 days. Bleeding occurs on the 7th-10th day after discontinuation of progesterone. For the treatment of functional uterine bleeding, 100 mg of progesterone is prescribed daily intravaginally for 5-7 days. Treatment should continue for 2-3 months, with a progesterone dose of 100 mg daily taken intravaginally from day 15-25 of the cycle. For endometriosis, 100-200 mg of progesterone is prescribed daily intravaginally as continuous therapy for 6 months. In case of spontaneous or threatened abortion, during anovulatory and induced cycles, 100-300 mg of intravaginal progesterone daily. Treatment is carried out continuously until the 18th-20th week of pregnancy. In vitro fertilization, 150-200 mg of progesterone is prescribed twice daily intravaginally. Treatment continues until the 77th day after embryo transfer. Treatment should be completed with gradual dose reduction. Indications: • Menstrual cycle disorders caused by endogenous progesterone deficiency, painful menstruation (dysmenorrhea), anovulatory cycles, premenstrual syndrome, functional uterine bleeding • Endometriosis • In vitro fertilization, luteal phase support during preparation for in vitro fertilization • Luteal phase deficiency • Prevention of spontaneous or threatened abortion • Luteal phase deficiency in the perimenopausal period • Hormone replacement therapy in postmenopausal women with an intact uterus Method of use: Luteina should be inserted into the vagina using the provided applicator. In pregnant women, due to a swollen cervix, it is recommended to use Luteina with the index finger. Side effects: Drowsiness, headache and dizziness, decreased concentration and attention, anxiety, depression, vaginal problems (irritation, itching, discharge). Contraindications: Allergic reactions to progesterone or any other component of the preparation, non-physiological vaginal bleeding. In case of suspected retained tissue in the uterus after spontaneous abortion, ectopic pregnancy, breast or genital tract tumors, blood clots in the arms, legs, lungs or other parts of the body, acute liver failure, lactation period. Pregnancy and lactation: Progesterone can be safely used in the first trimester of pregnancy. The use of progesterone during lactation is contraindicated, as this hormone is excreted in breast milk.